Seher KAYA

Dr. Seher KAYA

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKSalih Karatlı
Salih Karatlı
DYDoğan Yazılıtaş
Doğan Yazılıtaş
SKSeher KAYA
Seher KAYA
EBEngin Yasin Baraklı
Engin Yasin Baraklı
SÇselahattin çelik
selahattin çelik
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
Background: Unplanned hospitalizations in patients with cancer are associated with adverse outcomes, including intensive care unit (ICU) transfer and in-hospital mortality. This study aimed to evaluate the predictive role of the prognostic nutritional index (PNI) and albumin-to-globulin ratio (AGR) for these outcomes in patients with unplanned hospitalization in a medical oncology ward. Methods: This retrospective, single-center study included patients aged ≥18 years with malignancy who had unplanned hospitalization between 1 January and 30 April 2025. PNI and AGR were calculated at admission. The primary outcome was ICU transfer or in-hospital mortality. Univariable and multivariable logistic regression analyses were performed, with AGR and PNI evaluated in separate models to avoid collinearity. Predictive performance was assessed using ROC analysis. Results: A total of 418 patients were included, with adverse clinical outcomes in 26.8%. Metastatic disease was present in 73.7%, and gastrointestinal (41.6%) and lung cancers (21.5%) were most common. In univariable analysis, metastatic disease (p < 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (p < 0.001), cancer type (p = 0.030), reason for hospitalization (p = 0.001), AGR (p < 0.001), and PNI (p < 0.001) were significantly associated with adverse clinical outcomes. In multivariable analyses performed in separate models, ECOG ≥ 2 emerged as the strongest independent predictor of adverse clinical outcomes (AGR model: OR: 9.93; PNI model: OR: 11.14; both p < 0.001). Metastatic disease remained an independent risk factor, while higher AGR and PNI values were independently associated with a reduced risk (all p < 0.05). Among hospitalization reasons, only electrolyte imbalance/transfusion was associated with a lower risk, whereas most cancer type subgroups were not independently significant. Both indices showed moderate predictive performance, with PNI performing slightly better than AGR (AUC: 0.729 vs. 0.707). Conclusions: ECOG performance status, together with PNI and AGR, were identified as practical and accessible predictors of adverse clinical outcomes in patients with unplanned hospitalization in a medical oncology ward.

1 December 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MÖMerve kuday özkan
Merve kuday özkan
SKSeher KAYA
Seher KAYA
ÖDÖmer Dizdar
Ömer Dizdar

21 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SKSalih Karatlı
Salih Karatlı
SKSeher KAYA
Seher KAYA
SÇselahattin çelik
selahattin çelik
AIAysegul Ilhan
Aysegul Ilhan
OYOzgen Ahmet YILDIRIM
Ozgen Ahmet YILDIRIM
Background and Objectives: Immune checkpoint inhibitors (ICIs) improve survival in advanced non-small-cell lung cancer (NSCLC), yet treatment responses vary. The potential influence of proton pump inhibitors (PPIs), metformin, statins, and nonsteroidal anti-inflammatory drugs (NSAIDs) on immunotherapy efficacy has gained increasing attention. This study aimed to evaluate the associations of these medications with survival outcomes. Materials and Methods: This retrospective cohort study included 179 patients with advanced NSCLC who received second-line nivolumab. The use of PPIs, metformin, statins, and NSAIDs was assessed within a ±30-day exposure window around nivolumab initiation. Sensitivity analyses were performed including all four studied medications. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox regression models. Results: Median follow-up was 19 months, and 52.5% of patients used PPIs. In univariable analysis, PPI use was significantly associated with worse PFS (HR = 2.01; p < 0.001), while PD-L1 ≥ 50% expression was associated with improved PFS (HR = 0.57; p = 0.034). In multivariable analysis, PPI use remained independently associated with worse PFS (HR = 2.22; p < 0.001), and male sex was associated with improved PFS (HR = 0.56; p = 0.013). For OS, PPI use (HR = 1.53; p = 0.043), ECOG ≥ 2 (HR = 2.09; p = 0.001), and male sex (HR = 0.53; p = 0.008) were significant factors in univariable analysis. In multivariable analysis, PPI use (HR = 2.01; p = 0.002) and ECOG ≥ 2 (HR = 2.21; p = 0.001) were independent adverse prognostic factors, while male sex was independently associated with improved OS (HR = 0.41; p = 0.001). Median PFS was 5 months in PPI users versus 9 months in non-users (p < 0.001); median OS was 9 versus 14 months (p = 0.036). The use of metformin, statins, and NSAIDs showed no significant relationship with PFS or OS. Sensitivity analyses supported an association between PPI use and worse outcomes. Conclusions: PPI use was associated with worse PFS and OS in patients with advanced NSCLC receiving second-line nivolumab. These findings suggest that unnecessary PPI use should be carefully reassessed during immunotherapy.

1 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
GUGalip Uyar
Galip Uyar
GAGÜNER AKGÜNER
GÜNER AKGÜNER
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
SKSeher KAYA
Seher KAYA
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
Background: Systemic inflammation and nutritional status are key determinants of prognosis in metastatic clear-cell renal carcinoma (mccRCC). Composite indices such as the Systemic Immune–Inflammation Index (SII) and the Modified Glasgow Prognostic Score (mGPS) have demonstrated prognostic relevance across cancers, but real-world data in mccRCC remain limited. Methods: This retrospective, single-center cohort included patients with histologically confirmed mccRCC who received first-line tyrosine kinase inhibitor (TKI) monotherapy (sunitinib, pazopanib, or cabozantinib) between November 2022 and November 2024 at Etlik City Hospital (Ankara, Türkiye). Associations between inflammatory–nutritional indices (SII, mGPS) and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariable logistic regression analyses. Results: A total of 55 patients met eligibility criteria and were included in the analysis. The median age was 62 years (IQR 52–71), and 67% were male. Median PFS was 13.24 months (95% CI 7.75–19.12), while median OS was not reached. High SII (≥ 870) was independently associated with shorter PFS in multivariable analysis (OR 5.05; 95% CI 1.14–15.77; p = 0.039). mGPS (1–2) was significantly associated with inferior PFS in Kaplan–Meier analysis (HR 3.43; 95% CI 1.42–8.30; p = 0.006; log-rank p = 0.001), but lost significance in multivariable modeling. Metformin use (OR 0.12; 95% CI 0.02–0.93; p = 0.044), sunitinib therapy (OR 0.07; 95% CI 0.006–0.74; p = 0.027), and favorable/intermediate IMDC risk group (OR 0.17; 95% CI 0.06–0.96; p = 0.047) were independently associated with a lower progression risk. Patients treated with cabozantinib (n = 15) showed a numerically longer median PFS (18.6 months; 95% CI 13.8–23.3) compared with sunitinib (n = 25, 12.2 months; 95% CI 5.5–19.0) and pazopanib (n = 15, 12.1 months; 95% CI 6.7–17.5), although this difference was not statistically significant (log-rank p = 0.152). Conclusion: In this real-world cohort of patients with mccRCC treated with first-line TKI, host-related inflammatory and nutritional status were closely associated with progression-free survival. Additionally, patients classified within the favorable IMDC risk group exhibited a significantly lower risk of progression, highlighting the importance of integrating clinical risk stratification with systemic inflammatory and nutritional markers. Incorporating such easily measurable biomarkers and clinical risk scores into existing prognostic models may enhance individualized risk assessment and therapeutic decision-making. Future prospective, multicenter, randomized controlled, and artificial intelligence–assisted studies are warranted to validate these findings and refine precision oncology approaches in this population.

26 May 2026 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
MSmehmet furkan sağdıç
mehmet furkan sağdıç
ETEMRE TUNÇ
EMRE TUNÇ
SKSeher KAYA
Seher KAYA
MKMahmut Onur Kulturoglu
Mahmut Onur Kulturoglu
OYOzgen Ahmet YILDIRIM
Ozgen Ahmet YILDIRIM
LDLutfı Dogan
Lutfı Dogan
HER2-positive breast cancer accounts for 15-20% of all breast cancer cases. Anti-HER2-based neoadjuvant therapy combined with taxanes, particularly docetaxel and paclitaxel, constitutes the standard treatment approach. Although these regimens are widely used, most studies have focused on systemic adverse effects, with limited data addressing their impact on postoperative surgical complications. This study aimed to evaluate the association between docetaxel- and paclitaxel-based neoadjuvant regimens and early wound complications in HER2-positive breast cancer patients. We retrospectively analyzed 139 patients with HER2-positive breast cancer who underwent breast-conserving surgery following neoadjuvant therapy at Ankara Etlik City Hospital between October 2022 and January 2025. Patients were grouped according to the taxane received (docetaxel, n = 95; paclitaxel, n = 44). Demographic, clinicopathologic characteristics, and early postoperative wound complications were compared. Major complications were defined as major wound dehiscence and skin necrosis. Associations between variables and major complications were evaluated using univariate analysis. Major complications were significantly more frequent in the docetaxel group compared to the paclitaxel group (9.5% vs. 0%, p = 0.022), while no significant difference was observed in minor complications (p = 0.704). In subgroup analysis excluding patients who underwent axillary lymph node dissection, this association remained significant (11.1% vs. 0%, p = 0.034). Docetaxel-based neoadjuvant therapy was associated with a higher rate of major postoperative wound complications compared with paclitaxel-based regimens in patients with HER2-positive breast cancer. This association persisted after excluding patients who underwent axillary lymph node dissection. These findings should be interpreted with caution due to the retrospective design and limited number of events.

2 June 2026 in Medicina
Verified
Journal Article
Open access
PDF file
BDBENGU DURSUN
BENGU DURSUN
SKSeher KAYA
Seher KAYA
FAFerit Aydin
Ferit Aydin
AAAta Türker Arıkök
Ata Türker Arıkök
Background and Objectives: The optimal timing of surgery after preoperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy (ChT) in gastric cancer (GC) remains unclear. We aimed to evaluate the association between time to surgery (TTS) and pathological as well as survival outcomes in patients treated with perioperative FLOT. Materials and Methods: This retrospective cohort study included 76 patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who underwent curative-intent surgery after preoperative FLOT at a single tertiary center. TTS was defined as the interval between completion of preoperative FLOT and surgery. Patients were categorized into two groups according to TTS: ≤4 weeks and >4 weeks. Pathological response (PR) was assessed using the Becker tumor regression grading system. The primary endpoint was PR, including tumor regression grade and pathological complete response (pCR). Secondary endpoint was overall survival (OS). Results: The median TTS was 31 days (IQR, 21–47). Forty-five (59.2%) patients underwent surgery within 4 weeks. Favorable PR was more frequently observed in the ≤4-week group. Becker TRG 0–1 was significantly more common among patients undergoing surgery within 4 weeks compared with those undergoing surgery after more than 4 weeks (26.2% vs. 6.5%, p = 0.03). Similarly, pCR was observed exclusively in the ≤4-week group (14.3% vs. 0%, p = 0.02). ypN0 status was numerically higher in the ≤4-week group (54.7% vs. 32.2%, p = 0.05). Postoperative complication rates did not differ significantly between groups (4.8% vs. 12.9%, p = 0.17). In multivariable Cox regression analysis, TTS was not independently associated with OS, whereas poor tumor differentiation remained an independent predictor of worse survival (HR 2.57, 95% CI 1.17–5.63, p = 0.01). Conclusions: Among patients treated with preoperative FLOT, surgery within 4 weeks was associated with improved PR without an apparent increase in postoperative morbidity. However, earlier surgery was not independently associated with improved OS. These findings suggest that prolonged delay after preoperative FLOT may not be necessary in clinically recovered patients and support the need for prospective multicenter studies to define the optimal surgical interval in FLOT-treated GC.